We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Wins Landmark Approval With First Personalized CAR-T Cancer Therapy
Novartis Wins Landmark Approval With First Personalized CAR-T Cancer Therapy
The FDA opened the doors to a dramatic new method for treating cancer — the genetic modification of a patient’s immune cells to fight the disease — by granting approval to Novartis’ Kymriah.